Uehara Mayuko, McGrath Martina M
Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA, 02115, USA.
Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA, 02115, USA.
Clin Lab Med. 2019 Mar;39(1):87-106. doi: 10.1016/j.cll.2018.10.009. Epub 2018 Dec 22.
Costimulation is a critical step in T-cell activation, and costimulatory blockade at the time of T cell activation leads to T-cell anergy and allograft tolerance in animal models of transplantation. CD28:B7 is the most important costimulatory pathway and the balance of signals between CD28 and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) is a central determinant of transplant outcome. Form a clinical standpoint, CTLA-4 Ig is the only approved agent for costimulation blockade in transplantation. Advantages and disadvantages of its use are discussed. Progress in developing novel agents to target other pathways, including the promising CD40:CD154 pathway, is also discussed.
共刺激是T细胞活化的关键步骤,在T细胞活化时进行共刺激阻断可导致动物移植模型中的T细胞无反应性和同种异体移植耐受。CD28:B7是最重要的共刺激途径,CD28与细胞毒性T淋巴细胞相关蛋白4(CTLA-4)之间信号的平衡是移植结果的核心决定因素。从临床角度来看,CTLA-4 Ig是移植中共刺激阻断的唯一获批药物。文中讨论了其使用的优缺点。还讨论了开发针对其他途径的新型药物的进展,包括前景广阔的CD40:CD154途径。